Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Cseh, Anna-Maria [VerfasserIn]   i
 Niemeyer, Charlotte [VerfasserIn]   i
 Yoshimi-Nöllke, Ayami [VerfasserIn]   i
 Catala, Albert [VerfasserIn]   i
 Frühwald, Michael C. [VerfasserIn]   i
 Hasle, Henrik [VerfasserIn]   i
 Heuvel-Eibrink, Mary M. van den [VerfasserIn]   i
 Lauten, Melchior Johannes [VerfasserIn]   i
 De Moerloose, Barbara [VerfasserIn]   i
 Smith, Owen P. [VerfasserIn]   i
 Bernig, Toralf [VerfasserIn]   i
 Gruhn, Bernd [VerfasserIn]   i
 Kulozik, Andreas [VerfasserIn]   i
 Metzler, Markus [VerfasserIn]   i
 Olcay, Lale [VerfasserIn]   i
 Suttorp, Meinolf [VerfasserIn]   i
 Furlan, Ingrid [VerfasserIn]   i
 Strahm, Brigitte [VerfasserIn]   i
 Flotho, Christian [VerfasserIn]   i
Titel:Therapy with low-dose azacitidine for MDS in children and young adults
Titelzusatz:a retrospective analysis of the EWOG-MDS study group
Verf.angabe:Annamaria M. Cseh, Charlotte M. Niemeyer, Ayami Yoshimi, Albert Catala, Michael C. Frühwald, Henrik Hasle, Mary M. van den Heuvel-Eibrink, Melchior Lauten, Barbara De Moerloose, Owen P. Smith, Toralf Bernig, Bernd Gruhn, Andreas E. Kulozik, Markus Metzler, Lale Olcay, Meinolf Suttorp, Ingrid Furlan, Brigitte Strahm and Christian Flotho
E-Jahr:2016
Jahr:13 January 2016
Umfang:7 S.
Titel Quelle:Enthalten in: British journal of haematology
Ort Quelle:Oxford [u.a.] : Wiley-Blackwell, 1955
Jahr Quelle:2016
Band/Heft Quelle:172(2016), 6, Seite 930-936
ISSN Quelle:1365-2141
Abstract:Low-dose azacitidine is efficient and safe in the therapy of malignant myeloid disorders in adults but data in children are lacking. We present a retrospective analysis of 24 children and young adults with myelodysplastic syndrome (MDS) who received azacitidine at the time of first diagnosis or relapse after allotransplant (2 children were treated with azacitidine both initially and for relapse). Diagnoses were refractory cytopenia of childhood (N = 4), advanced primary MDS (N = 9) and secondary MDS (N = 11). The median duration of treatment was four cycles. Azacitidine was well tolerated, but cytopenias led to dose reduction in five cases. Treatment was discontinued in one child because of impaired renal function. Sixteen MDS patients were treated with azacitidine at first diagnosis. One complete clinical remission was observed and one child showed complete marrow remission; six children experienced stable disease with haematological improvement. Ten children received azacitidine for relapsed MDS after transplant: of these, seven experienced stable disease for 2-30 cycles (median 3), including one patient with haematological improvement for seven cycles. In summary, azacitidine is effective in some children with MDS and appears to be a non-toxic option in palliative situations to prolong survival.
DOI:doi:10.1111/bjh.13915
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext ; Verlag: http://dx.doi.org/10.1111/bjh.13915
 Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.13915
 DOI: https://doi.org/10.1111/bjh.13915
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1023791633
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68636164   QR-Code
zum Seitenanfang